U.S. Hospitality Stock News

Cogent Biosciences (COGT) has drawn fresh attention after submitting a New Drug Application to the FDA for bezuclastinib in NonAdvanced Systemic Mastocytosis, supported by statistically significant SUMMIT trial data and its prior Breakthrough Therapy Designation. See our latest analysis for Cogent Biosciences. The share price sits at $35.57 after a 90 day share price return of 118.62%, while the 1 year total shareholder return of 338.59% points to strong momentum building around bezuclastinib...

Installed Building Products, Inc. recently priced a US$500,000,000 offering of 5.625% senior unsecured notes due 2034, primarily to redeem its existing 5.75% senior unsecured notes due 2028 and cover related costs in a private placement under Rule 144A and Regulation S. This refinancing, paired with a recent S&P Global Ratings upgrade of the company’s credit rating, highlights a more flexible balance sheet and potentially lower long-term financing costs. Now we’ll examine how IBP’s new 2034...

COPT Defense Properties (CDP) is back in focus after reporting 557,000 square feet of vacancy leasing in 2025, topping its latest target, along with new build-to-suit projects in Maryland and Texas. See our latest analysis for COPT Defense Properties. The recent leasing wins and build to suit projects appear to have caught investors' attention, with a 1 day share price return of 4.57% to US$29.51 and a 7.35% year to date share price return. The 5 year total shareholder return of 39.94% points...

Recent attention on Diebold Nixdorf (DBD) centers on its post restructuring rebound. Improving sentiment is tied to upcoming earnings expectations, contract renewals, software upgrades, and a focus on retail automation and cost discipline. See our latest analysis for Diebold Nixdorf. At a share price of $68.0, Diebold Nixdorf has paired a sharp early year setback with a 90 day share price return of 23.86%, while the 1 year total shareholder return of 61.64% signals momentum building around...

Western Alliance Bancorporation: Recent Returns in Focus Western Alliance Bancorporation (WAL) has drawn fresh attention as investors weigh its recent share performance, with the stock showing positive moves over the past week, month, past 3 months, and year. See our latest analysis for Western Alliance Bancorporation. The 1-year total shareholder return of 13.2% sits on top of strong recent momentum, with a 90-day share price return of 19.7%. This suggests investors are reassessing both...

Fortrea Holdings recently announced that its CEO, CFO, and SVP of Investor Relations participated in the J.P. Morgan Annual Healthcare Conference on January 13, 2025, presenting the business and taking investor questions via a webcasted session. At the same time, a series of more positive analyst views and higher earnings estimates have drawn fresh attention to Fortrea’s position in the global contract research market. We’ll now examine how the recent wave of analyst upgrades and earnings...

MUSC Health’s new multi year partnership with Baxter International (BAX) to deploy connected care technologies has pushed the stock into focus, as investors weigh what deeper bedside integration could mean for the business. See our latest analysis for Baxter International. The MUSC Health agreement lands at a time when sentiment around Baxter is trying to find its footing, with a 13.9% 1 month share price return and a 6.1% year to date share price return contrasting with a 28.8% 1 year total...

After a soft showing around Valentine’s Day last year, Victoria's Secret (VSCO) is putting more emphasis on this February’s holiday, a key test for its lingerie focused retail model and investor expectations. See our latest analysis for Victoria's Secret. That renewed Valentine’s Day push comes as Victoria's Secret’s share price has climbed to $62.81, with a 90 day share price return of 122.34% and a 1 year total shareholder return of 63.19%, hinting that investors are reassessing both growth...

Praxis Precision Medicines recently priced and completed a very large follow-on equity offering of 2,212,000 common shares at US$260 each, raising about US$575.12 million to support its central nervous system pipeline, while also securing FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor and advancing toward an NDA filing in early 2026. On top of this capital raise, Praxis reshaped its leadership bench by adding former Pfizer CEO Jeffrey Kindler and veteran...

Flywire (FLYW) has been back on traders’ screens after third quarter results topped analyst expectations and the company deepened its TenPay Global partnership to support cross border tuition payments for Chinese students. See our latest analysis for Flywire. At a share price of $14.46, Flywire’s recent 90 day share price return of 15.04% and 30 day return of 6.40% suggest building momentum. However, the 1 year total shareholder return of 22.76% and 3 year total shareholder return of 43.84%...

UL Solutions recently launched a plug-in solar system testing and certification program based on UL 3700, creating a dedicated safety and performance framework for plug-in, or balcony, solar equipment connecting via standard household outlets. This move positions UL Solutions at the center of emerging U.S. policy efforts on plug-in solar, potentially giving manufacturers and regulators a common standard to enable safer, wider adoption among renters and homeowners. We’ll now explore how this...

Vornado Realty Trust (VNO) has drawn fresh attention after recent trading left the stock roughly flat over the past month and lower over the past 3 months, despite a positive 3 year total return. See our latest analysis for Vornado Realty Trust. That recent 2.88% one day and 4.0% seven day share price return has come after a softer patch. The year to date share price return of 3.47% contrasts with an 11.43% decline in the one year total shareholder return and a 60.51% gain over three years...

If you are asking yourself whether Capital One Financial is fairly priced today or not, you are in the right place to make sense of the numbers before you act. The stock last closed at US$255.68, with returns of 5.5% over 7 days, 10.8% over 30 days, 3.1% year to date, 43.7% over 1 year and 144.5% over 5 years, which naturally raises questions about how much of this performance is already reflected in the share price. Recent coverage has focused on how established lenders like Capital One...

In recent months, multiple law firms have filed securities class action lawsuits against Integer Holdings, alleging that the company made false and misleading statements about its competitive position and growth prospects in the electrophysiology device market between July 25, 2024 and October 22, 2025. This wave of litigation raises questions about the reliability of Integer’s prior disclosures on a market segment that had been positioned as a long-term growth driver. Next, we’ll examine...

Without a specific news headline driving attention today, Universal (UVV) still attracts interest as a long-standing agriproducts supplier. Shares last closed at $54.26 and the company has a reported value score of 4. See our latest analysis for Universal. The recent 1-day share price return of 2.13% sits alongside a steady year-to-date share price return of 3.20%, while the 1-year total shareholder return of 11.09% and 5-year total shareholder return of 37.20% indicate gradually building...

Adaptive Biotechnologies (ADPT) is back in focus after announcing two non-exclusive collaborations with Pfizer on T-cell receptor discovery and immune data licensing, as well as a new Series A financing round for its Digital Biotechnologies subsidiary. See our latest analysis for Adaptive Biotechnologies. At a share price of $15.96, Adaptive Biotechnologies has seen a 30 day share price return of 7.40% and a 1 year total shareholder return of 138.56%. Recent collaborations and financing news...

Regulatory catalysts and pipeline progress put MannKind (MNKD) in focus MannKind (MNKD) recently outlined a series of 2026 growth drivers, centering on upcoming FDA decisions for Afrezza and FUROSCIX ReadyFlow, as well as updates across several clinical and preclinical respiratory programs. See our latest analysis for MannKind. The recent update on Afrezza, FUROSCIX ReadyFlow and the broader respiratory pipeline comes as MannKind’s share price sits at US$6.01, with a 90 day share price return...

AllianceBernstein Holding (AB) has drawn fresh attention after appointing Onur Erzan as President, expanding his remit across business transformation, distribution and new product lines such as active ETFs and insurance asset management. See our latest analysis for AllianceBernstein Holding. The latest leadership change comes as AllianceBernstein Holding’s share price, at about US$38.40, has seen a 30 day share price return decline of 5.4%, while the 1 year total shareholder return of 13.8%...

Recently, Travel + Leisure Co. announced a lower interest rate on its 2024 Term Loan B Facility while maintaining the existing maturity, alongside active share repurchases and ongoing dividend increases that underscore its current capital allocation priorities. These moves coincided with fresh analyst attention, including upgraded and new coverage, highlighting how the company’s balance sheet management and shareholder return policy are influencing how the market views its business model...

What Murphy Oil (MUR) investors may be watching now Murphy Oil (MUR) has posted mixed recent returns, with a roughly flat move over the past month but a gain over the past 3 months, putting the stock back on some investors’ radar. See our latest analysis for Murphy Oil. The recent 9.43% 1 day share price return and 22.30% 90 day share price return at around $32.74 sit against a more modest 5.14% 1 year total shareholder return and a weaker 3 year total shareholder return, suggesting momentum...

Mizuho’s downgrade of Roper Technologies (ROP) and its reduced rating outlook have put fresh attention on the stock, after the move coincided with a share price decline and mixed signals from other analyst and short interest data. See our latest analysis for Roper Technologies. The downgrade lands on top of a softer trend, with the 90 day share price return of Roper Technologies at a 14.64% decline and the 1 year total shareholder return at a 14.30% decline. This suggests recent momentum has...

Investors may be wondering if Kinsale Capital Group at around US$411 a share still offers value, or if most of the easy gains are already behind it. The stock has recently seen a 5.1% move over the last 7 days, 10.5% over 30 days and 4.8% year to date, while the 1 year return sits at a 2.4% decline and the 3 year and 5 year returns are 42.9% and 107.0% respectively. These price moves come as investors continue to track Kinsale Capital Group's position in the specialty insurance space and...

In recent days, EQT has come under pressure as weaker U.S. natural gas prices, driven by milder winter weather forecasts, weighed on producer margins and investor sentiment. Despite this softness in the commodity backdrop and a pause after a multi-month rally, analysts remain broadly constructive on EQT’s longer-term fundamentals and cash flow focus. Next, we’ll examine how this weather-driven softness in natural gas prices may influence EQT’s existing investment narrative and risk-reward...

On 8 January 2026, GreyOrange and Zebra Technologies announced a partnership that combines Zebra’s SmartLens overhead RFID system with GreyOrange’s gStore platform to deliver near-real-time, item-level inventory visibility and automated in-store tasking for retailers. An early rollout at a national fashion retailer reportedly achieved on-shelf availability of up to 98%, highlighting how the solution could reduce manual counts, cut order cancellations, and boost store labor efficiency while...